Back to CLDX Stock Lookup
Pages: 1 2 »» Last Page

Celldex (CLDX) – Company Press Releases

Sep 23, 2016 11:30 AM Celldex Therapeutics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable
Aug 11, 2016 08:01 AM Celldex Appoints Elizabeth Crowley as Chief Product Development Officer
Aug 8, 2016 04:01 PM Celldex Reports Second Quarter 2016 Results
Aug 2, 2016 04:30 PM Celldex to Report Second Quarter 2016 Financial Results and Host Corporate 2016 Objectives Update Call
Jul 11, 2016 04:01 PM Celldex Therapeutics Initiates Phase 1/2 Clinical Trial of New Product Candidate CDX-014 in Advanced Renal Cell Carcinoma
Jul 7, 2016 04:01 PM Celldex Therapeutics to Participate in the Cantor Fitzgerald 2nd Annual Healthcare Conference
Jun 4, 2016 02:02 PM Celldex Therapeutics’ CDX‑1401, CDX‑301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients with Melanoma
May 5, 2016 08:01 AM Celldex Reports First Quarter 2016 Results
Apr 27, 2016 08:00 AM Celldex Therapeutics Initiates Phase 1/2 Study of Glembatumumab Vedotin in Squamous Cell Lung Cancer
Apr 20, 2016 08:30 AM Celldex Therapeutics Presents Data Supporting the Clinical Development of Glembatumumab Vedotin and the Preclinical CD40 Program at the AACR Annual Meeting 2016
Apr 18, 2016 09:00 AM Celldex Therapeutics Presents Favorable Safety Profile and Immune Response Data from Phase 1/2 Study of Varlilumab and Nivolumab at the AACR Annual Meeting 2016
Mar 17, 2016 04:01 PM Celldex Therapeutics to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2016
Mar 7, 2016 07:00 AM Data Safety and Monitoring Board Recommends Celldex’s Phase 3 Study of RINTEGA® (rindopepimut) in Newly Diagnosed Glioblastoma be Discontinued as it is Unlikely to Meet Primary Overall Survival End
Mar 3, 2016 05:03 PM Celldex Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference
Feb 25, 2016 07:00 AM Celldex Reports Fourth Quarter and Year-End 2015 Results
Feb 20, 2016 08:00 AM Celldex Presents Preliminary Cohort Data from Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Harvest at the 2016 BMT Tandem Meeting
Feb 18, 2016 04:01 PM Celldex to Report Fourth Quarter and Year-End 2015 Business/Financial Results and Host 2016 Corporate Strategy Conference Call
Feb 4, 2016 04:01 PM Celldex Therapeutics to Present at the Leerink Partners 5th Annual Global Healthcare Conference
Dec 8, 2015 08:59 AM Celldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Atezolizumab in Renal Cell Carcinoma
Dec 8, 2015 08:59 AM Celldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Atezolizumab in Renal Cell Carcinoma
Nov 20, 2015 02:30 PM Long-term Survival Benefit Demonstrated in Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma
Nov 20, 2015 02:30 PM Long-term Survival Benefit Demonstrated in Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma
Nov 6, 2015 07:00 AM Celldex Presents Varlilumab Mechanism Data at SITC Annual Meeting 2015
Nov 6, 2015 07:00 AM Celldex Presents Varlilumab Mechanism Data at SITC Annual Meeting 2015
Nov 5, 2015 04:45 PM Celldex Reports Third Quarter 2015 Results
Nov 5, 2015 04:45 PM Celldex Reports Third Quarter 2015 Results
Sep 30, 2015 03:35 PM Celldex Therapeutics to Present at the Leerink Partners Immuno-Oncology Roundtable
Sep 30, 2015 03:35 PM Celldex Therapeutics to Present at the Leerink Partners Immuno-Oncology Roundtable
Aug 10, 2015 04:01 PM Celldex Reports Second Quarter 2015 Results
Aug 4, 2015 09:20 AM Celldex to Report Second Quarter 2015 Financial Results and Host Corporate 2015 Objectives Update Call
Aug 4, 2015 09:20 AM Celldex to Report Second Quarter 2015 Financial Results and Host Corporate 2015 Objectives Update Call
Jul 2, 2015 08:00 AM Celldex Therapeutics to Present at the Cantor Fitzgerald Inaugural Healthcare Conference
Jul 2, 2015 08:00 AM Celldex Therapeutics to Present at the Cantor Fitzgerald Inaugural Healthcare Conference
Jul 1, 2015 08:00 AM Celldex Therapeutics Appoints Richard Wright as Chief Commercial Officer
Jun 29, 2015 08:00 AM Independent Data Safety and Monitoring Board Recommends Continuation of Celldex's Phase 3 Study of RINTEGA(R) (rindopepimut) in Newly Diagnosed Glioblastoma
Jun 29, 2015 08:00 AM Independent Data Safety and Monitoring Board Recommends Continuation of Celldex's Phase 3 Study of RINTEGA(R) (rindopepimut) in Newly Diagnosed Glioblastoma
May 31, 2015 09:00 AM Randomized Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Overall Survival and Emergence of Long-term Survival Benefit; Primary En
May 31, 2015 09:00 AM Randomized Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Overall Survival and Emergence of Long-term Survival Benefit; Primary En
May 28, 2015 09:21 AM Celldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Sunitinib in Metastatic Clear Cell Renal Cell Carcinoma
May 28, 2015 09:21 AM Celldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Sunitinib in Metastatic Clear Cell Renal Cell Carcinoma
May 27, 2015 04:01 PM Celldex Therapeutics to Present at the Jefferies 2015 Global Healthcare Conference
May 27, 2015 04:01 PM Celldex Therapeutics to Present at the Jefferies 2015 Global Healthcare Conference
May 13, 2015 05:08 PM Celldex Therapeutics to Present Data from the ReACT Study at 2015 ASCO Annual Meeting
May 13, 2015 05:08 PM Celldex Therapeutics to Present Data from the ReACT Study at 2015 ASCO Annual Meeting
Apr 29, 2015 08:01 AM Celldex Reports First Quarter 2015 Results
Apr 29, 2015 08:01 AM Celldex Reports First Quarter 2015 Results
Apr 20, 2015 08:01 AM Celldex's Varlilumab Demonstrates Synergistic Anti-Tumor Activity with PD-1 Signaling Blockade in Preclinical Studies
Apr 20, 2015 08:01 AM Celldex's Varlilumab Demonstrates Synergistic Anti-Tumor Activity with PD-1 Signaling Blockade in Preclinical Studies
Apr 6, 2015 04:01 PM Celldex Therapeutics' Phase 2 EMERGE Study of Glembatumumab Vedotin in Metastatic Breast Cancer Published in Journal of Clinical Oncology
Apr 6, 2015 04:01 PM Celldex Therapeutics' Phase 2 EMERGE Study of Glembatumumab Vedotin in Metastatic Breast Cancer Published in Journal of Clinical Oncology
Pages: 1 2 »» Last Page

Back to CLDX Stock Lookup